✦ LIBER ✦

ProtEx™ technology for the generation of novel therapeutic cancer vaccines

✍ Scribed by Rich-Henry Schabowsky; Rajesh K. Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S. Yolcu; Haval Shirwan

Book ID: 113956616
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 465 KB
Volume: 86
Category: Article
ISSN: 0014-4800
DOI: 10.1016/j.yexmp.2009.01.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outlining novel scenarios for improved t

Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm

✍ Baxevanis, Constantin N 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 668 KB

Development of a Novel Nanoparticle-base

Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy

✍ Zupančič, Eva; Silva, JoanaM; Videira, Mafalda A.; Moreira, João N.; Florindo, H 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 271 KB

Novel Immune Potentiators and Delivery T

Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines || Strategies for the Nonclinical Safety Assessment of Vaccines

✍ Singh, Manmohan 📂 Article 📅 2012 🏛 Springer US ⚖ 279 KB

Immunosuppressive mechanisms in cancer:

Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines

✍ Stefanie Gross; Astrid Geldmacher; Tumenjargal Sharav; Florian Losch; Peter Wald 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 102 KB

General Keynote: Vaccine Strategies for

General Keynote: Vaccine Strategies for the Therapy of Ovarian Cancer

✍ James W Hodge; Kwong-Yok Tsang; Diane J Poole; Jeffrey Schlom 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Development of Antibody-Based Therapeuti

Development of Antibody-Based Therapeutics || Technologies for the Generation of Human Antibodies

✍ Tabrizi, Mohammad A.; Bornstein, Gadi G.; Klakamp, Scott L. 📂 Article 📅 2012 🏛 Springer New York 🌐 English ⚖ 881 KB

The biologics market continues to witness an impressive rate of growth and the monoclonal antibody market, in particular, has contributed remarkably to the expansion of this segment within the pharmaceutical industry. In 2006, close to 80% of the annual biologics growth rate in the United States (US